Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.51 |
| ▸ | MMP9 | P14780 | 9/20 | 0.51 |
| ▸ | MMP13 | P45452 | 9/20 | 0.51 |
| ▸ | MMP3 | P08254 | 8/20 | 0.50 |
| ▸ | MMP7 | P09237 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634849 | 0.92 | MMP1 (0.52) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL5635339 | 0.91 | MMP1 (0.50) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL5634717 | 0.87 | GAA (0.46) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL4032820 | 0.85 | GAA (0.49) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL4033302 | 0.84 | MMP1 (0.48) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL4035027 | 0.83 | L3MBTL1 (0.47) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL4038558 | 0.83 | MMP1 (0.51) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL5634226 | 0.82 | MCHR1 (0.55) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL5635556 | 0.80 | MMP1 (0.53) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL4035430 | 0.79 | MMP1 (0.47) | MMP1MMP9MMP13MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | MMP1 3474/4885MMP9 4189/4885MMP13 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.